{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:55:34Z","timestamp":1768506934233,"version":"3.49.0"},"posted":{"date-parts":[[2023,11,8]]},"group-title":"Immunology","reference-count":115,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,11,8]]},"abstract":"<jats:title>Summary<\/jats:title>\n                <jats:p>Waning immunity and continued virus evolution have limited the durability of protection from symptomatic infection mediated by intramuscularly (IM)-delivered mRNA vaccines against COVID-19 although protection from severe disease remains high. Mucosal vaccination has been proposed as a strategy to increase protection at the site of SARS-CoV-2 infection by enhancing airway immunity, potentially reducing rates of infection and transmission. Here, we compared protection against XBB.1.16 virus challenge 5 months following IM or mucosal boosting in non-human primates (NHP) that had previously received a two-dose mRNA-1273 primary vaccine regimen. The mucosal boost was composed of a bivalent chimpanzee adenoviral-vectored vaccine encoding for both SARS-CoV-2 WA1 and BA.5 spike proteins (ChAd-SARS-CoV-2-S) and delivered either by an intranasal mist or an inhaled aerosol. An additional group of animals was boosted by the IM route with bivalent WA1\/BA.5 spike-matched mRNA (mRNA-1273.222) as a benchmark control. NHP were challenged in the upper and lower airways 18 weeks after boosting with XBB.1.16, a heterologous Omicron lineage strain. Cohorts boosted with ChAd-SARS-CoV-2-S by an aerosolized or intranasal route had low to undetectable virus replication as assessed by levels of subgenomic SARS-CoV-2 RNA in the lungs and nose, respectively. In contrast, animals that received the mRNA-1273.222 boost by the IM route showed minimal protection against virus replication in the upper airway but substantial reduction of virus RNA levels in the lower airway. Immune analysis showed that the mucosal vaccines elicited more durable antibody and T cell responses than the IM vaccine. Protection elicited by the aerosolized vaccine was associated with mucosal IgG and IgA responses, whereas protection elicited by intranasal delivery was mediated primarily by mucosal IgA. Thus, durable immunity and effective protection against a highly transmissible heterologous variant in both the upper and lower airways can be achieved by mucosal delivery of a virus-vectored vaccine. Our study provides a template for the development of mucosal vaccines that limit infection and transmission against respiratory pathogens.<\/jats:p>\n                <jats:sec>\n                  <jats:title>Graphical abstract<\/jats:title>\n                  <jats:fig id=\"ufig1\" position=\"float\" orientation=\"portrait\" fig-type=\"figure\">\n                    <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"565765v1_ufig1\" position=\"float\" orientation=\"portrait\"\/>\n                  <\/jats:fig>\n                <\/jats:sec>","DOI":"10.1101\/2023.11.06.565765","type":"posted-content","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T06:10:14Z","timestamp":1699423814000},"source":"Crossref","is-referenced-by-count":6,"title":["Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates"],"prefix":"10.64898","author":[{"given":"Matthew","family":"Gagne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara J.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shayne F.","family":"Andrew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dillon R.","family":"Flebbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Mychalowych","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan","family":"Lamb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith E.","family":"Davis-Gardner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R.","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonid A.","family":"Serebryannyy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bob C.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Pessaint","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John-Paul M.","family":"Todd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zohar E.","family":"Ziff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Maule","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mursal","family":"Naisan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogita","family":"Jethmalani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James Brett","family":"Case","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor P.","family":"Dmitriev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena A.","family":"Kashentseva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baoling","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Dodson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katelyn","family":"Kouneski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole A.","family":"Doria-Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sijy","family":"O\u2019Dell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sucheta","family":"Godbole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farida","family":"Laboune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy R.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josue","family":"Marquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I-Ting","family":"Teng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingshu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bushra","family":"Wali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madison","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serge","family":"Zouantchangadou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex Van","family":"Ry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark G.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanne","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter D.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David T.","family":"Curiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn E.","family":"Foulds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha C.","family":"Nason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2686-8380","authenticated-orcid":false,"given":"Mehul S.","family":"Suthar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Roederer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel C.","family":"Douek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Seder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2023111601151100000_2023.11.06.565765v1.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2115481"},{"key":"2023111601151100000_2023.11.06.565765v1.2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41467-023-35815-7","article-title":"Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5","volume":"14","year":"2023","journal-title":"Nat Commun"},{"key":"2023111601151100000_2023.11.06.565765v1.3","doi-asserted-by":"crossref","first-page":"e2232760","DOI":"10.1001\/jamanetworkopen.2022.32760","article-title":"Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes","volume":"5","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2023111601151100000_2023.11.06.565765v1.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02183-8\/ATTACHMENT\/E998365A-8F41-4C9C-997B-8F5A40D3AAD4\/MMC1.PDF"},{"key":"2023111601151100000_2023.11.06.565765v1.5","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1056\/NEJMc2302462","article-title":"Durability of Bivalent Boosters against Omicron Subvariants","volume":"388","year":"2023","journal-title":"N Engl J Med"},{"key":"2023111601151100000_2023.11.06.565765v1.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02051-3"},{"key":"2023111601151100000_2023.11.06.565765v1.7","first-page":"100461","article-title":"COVID-19 hospitalisations in immunocompromised individuals in the Omicron era: a population-based observational study using surveillance data in British Columbia","volume":"20","year":"2023","journal-title":"Canada. Lancet Reg Health Am"},{"key":"2023111601151100000_2023.11.06.565765v1.8","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1093\/cid\/ciac571","article-title":"Clinical Characteristics and Outcomes of Immunocompromised Patients With Coronavirus Disease 2019 Caused by the Omicron Variant: A Prospective, Observational Study","volume":"76","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023111601151100000_2023.11.06.565765v1.9","unstructured":"Griggs, E.P. et al. Clinical epidemiology and risk factors for critical outcomes among vaccinated and unvaccinated adults hospitalized with COVID-19-VISION Network, 10 States, June 2021-March 2023. Clin Infect Dis (2023)."},{"key":"2023111601151100000_2023.11.06.565765v1.10","doi-asserted-by":"crossref","first-page":"11327","DOI":"10.1038\/s41598-023-36990-9","article-title":"A population-scale temporal case-control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP)","volume":"13","year":"2023","journal-title":"Sci Rep"},{"key":"2023111601151100000_2023.11.06.565765v1.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2114228\/SUPPL_FILE\/NEJMOA2114228_DISCLOSURES.PDF"},{"key":"2023111601151100000_2023.11.06.565765v1.12","doi-asserted-by":"publisher","DOI":"10.1101\/2021.09.17.21263624"},{"key":"2023111601151100000_2023.11.06.565765v1.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109072"},{"key":"2023111601151100000_2023.11.06.565765v1.14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.10650"},{"key":"2023111601151100000_2023.11.06.565765v1.15","unstructured":"Corbett, K.S. et al. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science , eabj0299 (2021)."},{"key":"2023111601151100000_2023.11.06.565765v1.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.05.040"},{"key":"2023111601151100000_2023.11.06.565765v1.17","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1038\/s41467-023-41049-4","article-title":"Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography","volume":"14","year":"2023","journal-title":"Nat Commun"},{"key":"2023111601151100000_2023.11.06.565765v1.18","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","article-title":"Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity","volume":"184","year":"2021","journal-title":"Cell"},{"key":"2023111601151100000_2023.11.06.565765v1.19","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","article-title":"Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis","volume":"3","year":"2022","journal-title":"Lancet Microbe"},{"key":"2023111601151100000_2023.11.06.565765v1.20","first-page":"162","article-title":"SARS-CoV-2 variant biology: immune escape, transmission and fitness","volume":"21","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"2023111601151100000_2023.11.06.565765v1.21","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2105000"},{"key":"2023111601151100000_2023.11.06.565765v1.22","doi-asserted-by":"publisher","DOI":"10.1126\/science.abq1841"},{"key":"2023111601151100000_2023.11.06.565765v1.23","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.cell.2022.01.018","article-title":"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination","volume":"185","year":"2022","journal-title":"Cell"},{"key":"2023111601151100000_2023.11.06.565765v1.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06025-4"},{"key":"2023111601151100000_2023.11.06.565765v1.25","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41564-023-01359-1","article-title":"Fc-gammaR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2","volume":"8","year":"2023","journal-title":"Nat Microbiol"},{"key":"2023111601151100000_2023.11.06.565765v1.26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cell.2021.12.002","article-title":"Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung","volume":"185","year":"2022","journal-title":"Cell"},{"key":"2023111601151100000_2023.11.06.565765v1.27","doi-asserted-by":"crossref","first-page":"eabq7647","DOI":"10.1126\/sciimmunol.abq7647","article-title":"CD8 T cells contribute to vaccine protection against SARS-CoV-2 in macaques","volume":"7","year":"2022","journal-title":"Sci Immunol"},{"key":"2023111601151100000_2023.11.06.565765v1.28","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity","volume":"183","year":"2020","journal-title":"Cell"},{"key":"2023111601151100000_2023.11.06.565765v1.29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41541-023-00654-6","article-title":"Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities-workshop report","volume":"8","year":"2023","journal-title":"NPJ Vaccines"},{"key":"2023111601151100000_2023.11.06.565765v1.30","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(21)00472-2"},{"key":"2023111601151100000_2023.11.06.565765v1.31","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc2209651"},{"key":"2023111601151100000_2023.11.06.565765v1.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2213153"},{"key":"2023111601151100000_2023.11.06.565765v1.33","doi-asserted-by":"publisher","DOI":"10.1126\/science.abo2523"},{"key":"2023111601151100000_2023.11.06.565765v1.34","doi-asserted-by":"crossref","first-page":"eadh1655","DOI":"10.1126\/sciadv.adh1655","article-title":"Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection","volume":"9","year":"2023","journal-title":"Sci Adv"},{"key":"2023111601151100000_2023.11.06.565765v1.35","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1016\/j.cell.2022.11.006","article-title":"Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in monkeys","volume":"185","year":"2022","journal-title":"Cell"},{"key":"2023111601151100000_2023.11.06.565765v1.36","doi-asserted-by":"crossref","unstructured":"Ponce-de-Leon, S. et al. Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico. NPJ Vaccines 8, 67 (2023).","DOI":"10.1038\/s41541-023-00662-6"},{"key":"2023111601151100000_2023.11.06.565765v1.37","doi-asserted-by":"crossref","first-page":"104298","DOI":"10.1016\/j.ebiom.2022.104298","article-title":"Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial","volume":"85","year":"2022","journal-title":"EBioMedicine"},{"key":"2023111601151100000_2023.11.06.565765v1.38","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1473-3099(21)00396-0","article-title":"Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial","volume":"21","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2023111601151100000_2023.11.06.565765v1.39","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41541-023-00717-8","article-title":"Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin((R)))","volume":"8","year":"2023","journal-title":"NPJ Vaccines"},{"key":"2023111601151100000_2023.11.06.565765v1.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.026"},{"key":"2023111601151100000_2023.11.06.565765v1.41","doi-asserted-by":"crossref","first-page":"100230","DOI":"10.1016\/j.xcrm.2021.100230","article-title":"A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques","volume":"2","year":"2021","journal-title":"Cell Rep Med"},{"key":"2023111601151100000_2023.11.06.565765v1.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109400"},{"key":"2023111601151100000_2023.11.06.565765v1.43","doi-asserted-by":"crossref","unstructured":"Ying, B. et al. A bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ.1.1 and XBB.1.5 infection and disease in mice and hamsters. bioRxiv, 2023.2005.2004.539332 (2023).","DOI":"10.1101\/2023.05.04.539332"},{"key":"2023111601151100000_2023.11.06.565765v1.44","doi-asserted-by":"crossref","first-page":"109452","DOI":"10.1016\/j.celrep.2021.109452","article-title":"An intranasal vaccine durably protects against SARS-CoV-2 variants in mice","volume":"36","year":"2021","journal-title":"Cell Rep"},{"key":"2023111601151100000_2023.11.06.565765v1.45","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2324-7.Respiratory"},{"key":"2023111601151100000_2023.11.06.565765v1.46","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-01021-0"},{"key":"2023111601151100000_2023.11.06.565765v1.47","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.cell.2022.03.038","article-title":"mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron","volume":"185","year":"2022","journal-title":"Cell"},{"key":"2023111601151100000_2023.11.06.565765v1.48","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.abl8912","article-title":"Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates","volume":"374","year":"2021","journal-title":"Science"},{"key":"2023111601151100000_2023.11.06.565765v1.49","unstructured":"Chandrashekar, A. et al. Vaccine Protection Against the SARS-CoV-2 Omicron Variant in Macaques. bioRxiv, 2022.2002.2006.479285 (2022)."},{"key":"2023111601151100000_2023.11.06.565765v1.50","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03732-8"},{"key":"2023111601151100000_2023.11.06.565765v1.51","doi-asserted-by":"crossref","unstructured":"Routhu, N.K. , et al. Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates. Sci Immunol, eadg7015 (2023).","DOI":"10.1126\/sciimmunol.adg7015"},{"key":"2023111601151100000_2023.11.06.565765v1.52","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1038\/s41467-023-37715-2","article-title":"Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques","volume":"14","year":"2023","journal-title":"Nat Commun"},{"key":"2023111601151100000_2023.11.06.565765v1.53","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05715-3"},{"key":"2023111601151100000_2023.11.06.565765v1.54","doi-asserted-by":"crossref","unstructured":"Ying, B. , et al. A bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ.1.1 and XBB.1.5 infection and disease in mice and hamsters. bioRxiv (2023).","DOI":"10.1101\/2023.05.04.539332"},{"key":"2023111601151100000_2023.11.06.565765v1.55","doi-asserted-by":"crossref","first-page":"6309","DOI":"10.1038\/s41467-022-33985-4","article-title":"Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine","volume":"13","year":"2022","journal-title":"Nat Commun"},{"key":"2023111601151100000_2023.11.06.565765v1.56","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41591-022-01753-y","article-title":"Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants","volume":"28","year":"2022","journal-title":"Nat Med"},{"key":"2023111601151100000_2023.11.06.565765v1.57","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1056\/NEJMoa2201570","article-title":"Protection by a Fourth Dose of BNT162b2 against Omicron in Israel","volume":"386","year":"2022","journal-title":"N Engl J Med"},{"key":"2023111601151100000_2023.11.06.565765v1.58","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1016\/j.cell.2021.03.029","article-title":"Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein","volume":"184","year":"2021","journal-title":"Cell"},{"key":"2023111601151100000_2023.11.06.565765v1.59","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELL.2021.02.026"},{"key":"2023111601151100000_2023.11.06.565765v1.60","doi-asserted-by":"crossref","unstructured":"Schafer, A. et al. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. J Exp Med 218 (2021).","DOI":"10.1084\/jem.20201993"},{"key":"2023111601151100000_2023.11.06.565765v1.61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2114583"},{"key":"2023111601151100000_2023.11.06.565765v1.62","doi-asserted-by":"crossref","unstructured":"Pegu, A. et al. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science (2021).","DOI":"10.1101\/2021.05.13.444010"},{"key":"2023111601151100000_2023.11.06.565765v1.63","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1056\/NEJMc2108829","article-title":"Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination","volume":"385","year":"2021","journal-title":"N Engl J Med"},{"key":"2023111601151100000_2023.11.06.565765v1.64","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMc2115596","article-title":"Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines","volume":"385","year":"2021","journal-title":"N Engl J Med"},{"key":"2023111601151100000_2023.11.06.565765v1.65","doi-asserted-by":"crossref","first-page":"e488","DOI":"10.1016\/S2666-5247(23)00102-7","article-title":"Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose","volume":"4","year":"2023","journal-title":"Lancet Microbe"},{"key":"2023111601151100000_2023.11.06.565765v1.66","doi-asserted-by":"crossref","first-page":"104402","DOI":"10.1016\/j.ebiom.2022.104402","article-title":"SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination","volume":"87","year":"2023","journal-title":"EBioMedicine"},{"key":"2023111601151100000_2023.11.06.565765v1.67","unstructured":"Francica, J.R. et al. Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. Sci Transl Med 13 (2021)."},{"key":"2023111601151100000_2023.11.06.565765v1.68","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELL.2020.09.037"},{"key":"2023111601151100000_2023.11.06.565765v1.69","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2607z"},{"key":"2023111601151100000_2023.11.06.565765v1.70","doi-asserted-by":"crossref","first-page":"eabj9853","DOI":"10.1126\/science.abj9853","article-title":"Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells","volume":"374","year":"2021","journal-title":"Science"},{"key":"2023111601151100000_2023.11.06.565765v1.71","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj7211"},{"key":"2023111601151100000_2023.11.06.565765v1.72","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cell.2022.01.015","article-title":"SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron","volume":"185","year":"2022","journal-title":"Cell"},{"key":"2023111601151100000_2023.11.06.565765v1.73","doi-asserted-by":"crossref","first-page":"1146841","DOI":"10.3389\/fimmu.2023.1146841","article-title":"Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections","volume":"14","year":"2023","journal-title":"Front Immunol"},{"key":"2023111601151100000_2023.11.06.565765v1.74","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1126\/science.add2897","article-title":"T cell immunity to COVID-19 vaccines","volume":"377","year":"2022","journal-title":"Science"},{"key":"2023111601151100000_2023.11.06.565765v1.75","doi-asserted-by":"crossref","first-page":"eadd4853","DOI":"10.1126\/sciimmunol.add4853","article-title":"Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination","volume":"7","year":"2022","journal-title":"Sci Immunol"},{"key":"2023111601151100000_2023.11.06.565765v1.76","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41385-022-00511-0","article-title":"Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection","volume":"15","year":"2022","journal-title":"Mucosal Immunol"},{"key":"2023111601151100000_2023.11.06.565765v1.77","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2021.11.006"},{"key":"2023111601151100000_2023.11.06.565765v1.78","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00979-13"},{"key":"2023111601151100000_2023.11.06.565765v1.79","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.09.018"},{"key":"2023111601151100000_2023.11.06.565765v1.80","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.00900"},{"key":"2023111601151100000_2023.11.06.565765v1.81","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.11.1597"},{"key":"2023111601151100000_2023.11.06.565765v1.82","doi-asserted-by":"crossref","first-page":"852546","DOI":"10.3389\/falgy.2022.852546","article-title":"The Role of IgA in Chronic Upper Airway Disease: Friend or Foe?","volume":"3","year":"2022","journal-title":"Front Allergy"},{"key":"2023111601151100000_2023.11.06.565765v1.83","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.4.2328-2338.2001"},{"key":"2023111601151100000_2023.11.06.565765v1.84","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1128\/jcm.25.3.559-562.1987","article-title":"Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum","volume":"25","year":"1987","journal-title":"J Clin Microbiol"},{"key":"2023111601151100000_2023.11.06.565765v1.85","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1016\/j.immuni.2022.08.017","article-title":"Mucosal plasma cells are required to protect the upper airway and brain from infection","volume":"55","year":"2022","journal-title":"Immunity"},{"key":"2023111601151100000_2023.11.06.565765v1.86","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41586-021-04186-8","article-title":"Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2","volume":"601","year":"2022","journal-title":"Nature"},{"key":"2023111601151100000_2023.11.06.565765v1.87","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.08.008"},{"key":"2023111601151100000_2023.11.06.565765v1.88","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41541-019-0113-9","article-title":"Boosting BCG with proteins or rAd5 does not enhance protection against tuberculosis in rhesus macaques","volume":"4","year":"2019","journal-title":"NPJ Vaccines"},{"key":"2023111601151100000_2023.11.06.565765v1.89","doi-asserted-by":"crossref","first-page":"1246826","DOI":"10.3389\/fimmu.2023.1246826","article-title":"Spore-FP1 tuberculosis mucosal vaccine candidate is highly protective in guinea pigs but fails to improve on BCG-conferred protection in non-human primates","volume":"14","year":"2023","journal-title":"Front Immunol"},{"key":"2023111601151100000_2023.11.06.565765v1.90","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400676"},{"key":"2023111601151100000_2023.11.06.565765v1.91","doi-asserted-by":"publisher","DOI":"10.4161\/hv.29108"},{"key":"2023111601151100000_2023.11.06.565765v1.92","doi-asserted-by":"crossref","first-page":"100355","DOI":"10.1016\/j.xcrm.2021.100355","article-title":"Impact of SARS-CoV-2 variants on the total CD4(+) and CD8(+) T cell reactivity in infected or vaccinated individuals","volume":"2","year":"2021","journal-title":"Cell Rep Med"},{"key":"2023111601151100000_2023.11.06.565765v1.93","doi-asserted-by":"crossref","first-page":"eabj6824","DOI":"10.1126\/scitranslmed.abj6824","article-title":"Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity","volume":"14","year":"2022","journal-title":"Sci Transl Med"},{"key":"2023111601151100000_2023.11.06.565765v1.94","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41423-022-00838-5","article-title":"T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant","volume":"19","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"2023111601151100000_2023.11.06.565765v1.95","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jcf.2015.04.003","article-title":"Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients","volume":"14","year":"2015","journal-title":"J Cyst Fibros"},{"key":"2023111601151100000_2023.11.06.565765v1.96","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.09.109"},{"key":"2023111601151100000_2023.11.06.565765v1.97","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31825687b0"},{"key":"2023111601151100000_2023.11.06.565765v1.98","doi-asserted-by":"crossref","first-page":"eade0424","DOI":"10.1126\/scitranslmed.ade0424","article-title":"A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccine","volume":"14","year":"2022","journal-title":"Sci Transl Med"},{"key":"2023111601151100000_2023.11.06.565765v1.99","doi-asserted-by":"publisher","DOI":"10.1126\/science.1243283"},{"key":"2023111601151100000_2023.11.06.565765v1.100","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1707304114"},{"key":"2023111601151100000_2023.11.06.565765v1.101","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/23744235.2022.2140822","article-title":"Size distribution of exhaled aerosol particles containing SARS-CoV-2 RNA","volume":"55","year":"2023","journal-title":"Infect Dis (Lond)"},{"key":"2023111601151100000_2023.11.06.565765v1.102","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1038\/s41598-023-30702-z","article-title":"Size distribution and relationship of airborne SARS-CoV-2 RNA to indoor aerosol in hospital ward environments","volume":"13","year":"2023","journal-title":"Sci Rep"},{"key":"2023111601151100000_2023.11.06.565765v1.103","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02527-21"},{"key":"2023111601151100000_2023.11.06.565765v1.104","doi-asserted-by":"crossref","unstructured":"Wang, C.C. et al. Airborne transmission of respiratory viruses. Science 373 (2021).","DOI":"10.1126\/science.abd9149"},{"key":"2023111601151100000_2023.11.06.565765v1.105","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn1413"},{"key":"2023111601151100000_2023.11.06.565765v1.106","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1016\/j.vaccine.2020.09.018","article-title":"Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk\/benefit assessment","volume":"39","year":"2021","journal-title":"Vaccine"},{"key":"2023111601151100000_2023.11.06.565765v1.107","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb2507"},{"key":"2023111601151100000_2023.11.06.565765v1.108","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2019.01.013"},{"key":"2023111601151100000_2023.11.06.565765v1.109","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd0826"},{"key":"2023111601151100000_2023.11.06.565765v1.110","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(68)90121-9"},{"key":"2023111601151100000_2023.11.06.565765v1.111","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates","volume":"383","year":"2020","journal-title":"N Engl J Med"},{"key":"2023111601151100000_2023.11.06.565765v1.112","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1015536108"},{"key":"2023111601151100000_2023.11.06.565765v1.113","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.chom.2021.03.009","article-title":"Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant","volume":"29","year":"2021","journal-title":"Cell Host Microbe"},{"key":"2023111601151100000_2023.11.06.565765v1.114","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12250-020-00230-5","article-title":"On the Calculation of TCID50 for Quantitation of Virus Infectivity","volume":"36","year":"2021","journal-title":"Virologica Sinica"},{"key":"2023111601151100000_2023.11.06.565765v1.115","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.23670"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.11.06.565765","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:29:38Z","timestamp":1768454978000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2023.11.06.565765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,8]]},"references-count":115,"URL":"https:\/\/doi.org\/10.1101\/2023.11.06.565765","relation":{},"subject":[],"published":{"date-parts":[[2023,11,8]]},"subtype":"preprint"}}